Mersana Therapeutics has been granted a patent for antibody-drug conjugates containing pyrrolo[2, 1-c][1, 4]benzodiazepine (PBD) drug moieties. The patent also covers the use of these conjugates as therapeutics and/or diagnostics. GlobalData’s report on Mersana Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mersana Therapeutics, nanoparticle drug conjugates was a key innovation area identified from patents. Mersana Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody-drug conjugates with pyrrolo[2,1-c][1,4]benzodiazepine drug moieties
A recently granted patent (Publication Number: US11638760B2) discloses a conjugate formula for the treatment of cancer. The patent claims a conjugate of Formula (II), which includes various components and structures. The conjugate can have a terminal group WP, which is connected to LP. The conjugate may also contain a peptide moiety MA, consisting of three to ten amino acids selected from a specific group. Additionally, the conjugate may include a peptide LD, consisting of 1 to 12 amino acids selected from a specific group.
The hydrophilic group of the conjugate can be a polyalcohol, a derivative thereof, a polyether, a derivative thereof, or a combination of these. The conjugate may also include fragments of the formula T', which can have different variations and combinations. The PBD drug moiety (D) of the conjugate can correspond to various compounds of specific formulas.
The patent also claims a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable carrier. Furthermore, a method of treating cancer is disclosed, which involves administering a pharmaceutically effective amount of the conjugate to a subject in need.
This granted patent provides a specific conjugate formula for the treatment of cancer. The conjugate includes various components and structures, such as terminal groups, peptide moieties, hydrophilic groups, and PBD drug moieties. The patent also covers the use of the conjugate in a pharmaceutical composition and a method of treating cancer. This patent may have implications for the development of new cancer treatments and the improvement of existing therapies.
To know more about GlobalData’s detailed insights on Mersana Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
